# QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01315249** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 523 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** indacaterol and glycopyrronium (QVA149)
- **DRUG:** Placebo to fluticasone/salmeterol
- **DRUG:** fluticasone/salmeterol
- **DRUG:** Placebo to indacaterol and glycopyrronium (QVA149)

## Key facts

- **NCT ID:** NCT01315249
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 523 (ACTUAL)
- **Last updated:** 2013-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01315249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01315249, "QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01315249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*